Vivet will be attending and presenting during the 1st Annual Optimizing AAV Safety Summit in Boston.
With hundreds of clinical trials using AAV currently underway, it has never before been so important to create and implement an effective AAV safety strategy. Improving prediction of AAV toxicity, accurately monitoring potential safety signals, extracting safety data from non-clinical & clinical studies to streamline AAV safety processes and safeguard patient outcomes, are all reasons that bring key leaders together.
There will be 2 sessions with Jean-Philippe Combal, CEO and Co-Founder of Vivet Therapeutics:
1️⃣ Jean-Phillipe will chair a workshop "Demonstrating Appropriate Toxicity & Safety Data to Gain Regulatory Approval of AAV Therapies" and will answer key challenges by putting forward:
? Real life case studies from key companies demonstrating how they progressed their own AAV programs, including best practice for IND submissions and phase I – III clinical development programs.
2️⃣ Then he will present during "The lessons learned from Clinical Trials to Enlighten Development for AAV Gene Therapies" session with Katherine High, President – Askbio and Eric David, CEO - BridgeBio
? Lessons learned from both successes and setbacks (such as clinical holds) to improve gene therapy development moving forward
And on the 2nd day of the conference, Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer & Co-Founder of Vivet Therapeutics will also participate in 2 sessions:
1️⃣ Gloria will present "Strategies to Overcome the Action of Neutralizing Antibodies Against AAV" focused on several strategies under investigation to overcome this first barrier and unwanted side effects, and
2️⃣ Gloria will take part on the panel “Designing an Appropriate Immunosuppressive Regimen to Minimize Impact of the Immune Response to Administered AAV Therapies". Key questions will be answered such as:
? The best methods to circumvent the activation of both innate and adaptive immune response to the protein capsid, vector genome and transgene product to ensure no SAEs and reduce risk of clinical holds.
With hundreds of clinical trials using AAV currently underway, it has never before been so important to create and implement an effective AAV safety strategy. Improving prediction of AAV toxicity, accurately monitoring potential safety signals, extracting safety data from non-clinical & clinical studies to streamline AAV safety processes and safeguard patient outcomes, are all reasons that bring key leaders together.
There will be 2 sessions with Jean-Philippe Combal, CEO and Co-Founder of Vivet Therapeutics:
1️⃣ Jean-Phillipe will chair a workshop "Demonstrating Appropriate Toxicity & Safety Data to Gain Regulatory Approval of AAV Therapies" and will answer key challenges by putting forward:
? Real life case studies from key companies demonstrating how they progressed their own AAV programs, including best practice for IND submissions and phase I – III clinical development programs.
2️⃣ Then he will present during "The lessons learned from Clinical Trials to Enlighten Development for AAV Gene Therapies" session with Katherine High, President – Askbio and Eric David, CEO - BridgeBio
? Lessons learned from both successes and setbacks (such as clinical holds) to improve gene therapy development moving forward
And on the 2nd day of the conference, Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer & Co-Founder of Vivet Therapeutics will also participate in 2 sessions:
1️⃣ Gloria will present "Strategies to Overcome the Action of Neutralizing Antibodies Against AAV" focused on several strategies under investigation to overcome this first barrier and unwanted side effects, and
2️⃣ Gloria will take part on the panel “Designing an Appropriate Immunosuppressive Regimen to Minimize Impact of the Immune Response to Administered AAV Therapies". Key questions will be answered such as:
? The best methods to circumvent the activation of both innate and adaptive immune response to the protein capsid, vector genome and transgene product to ensure no SAEs and reduce risk of clinical holds.
Vivet will be attending the 2nd Gene Patient Engagement congress with Sonia VALERO, Head of Clinical Operations and Patient Advocacy.
On the agenda, very interesting sessions and roundtables are planned, notably:
• Unique Characteristics of Gene Therapy & Their Ethical Implications For Clinical Trial Participation & Post-Approval Access
• Setting & Managing Expectations of Gene Therapy Within The Patient Community
• Building a Patient-Driven Informed Consent Process for a Gene Therapy
• Building a Patient-Centered Clinical Trial Protocol
On the agenda, very interesting sessions and roundtables are planned, notably:
• Unique Characteristics of Gene Therapy & Their Ethical Implications For Clinical Trial Participation & Post-Approval Access
• Setting & Managing Expectations of Gene Therapy Within The Patient Community
• Building a Patient-Driven Informed Consent Process for a Gene Therapy
• Building a Patient-Centered Clinical Trial Protocol
Vivet Therapeutics, a clinical-stage biotech company dedicated to developing gene therapy
Vivet Therapeutics BD Director, Thomas Daniel-Robin
Vivet Therapeutics CEO, Jean-Philippe Combal, will be participating to a panel during 2021 World Orphan Drug Congress Europe in Barcelona (Nov 15-18).
VIVET THERAPEUTICS ANNOUNCES 2 ORAL PRESENTATIONS AND 4 ABSTRACTS AT 2021 ESGCT ANNUAL MEETING
Vivet CDO, Anne Douar, will be presenting
Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting
Jean-Philippe Combal, Vivet CEO, will be attending a panel during the Cell & Gene Meeting on the Med - virtual, organized by the ARM on April 6-9, 2021. The panel, "TRENDS AND CHALLENGES IN GENE THERAPY IN EUROPE", will be held on April 7, 3-4pm CET.